Access to biologic/ biosimilar medicines for people with 'moderate' RA
Published: 13 Feb 2019
The National Rheumatoid Arthritis Society and the British Society for Rheumatology have issued a joint statement today on the subject of access to biologic/biosimilar medicines for people with RA who have ‘moderate’ disease.
With the advent of biosimilars, the cost of TNF inhibitors and Rituximab have reduced considerably. In light of this, BSR and NRAS have met jointly with NICE and NHSE to ask them to review the threshold for biologic prescribing in RA to include those with moderate disease. As a result, the BSR has been asked to provide further information on the likely demand if the current DAS threshold of 5.1 were lowered. We will be working with partners to estimate the likely consequence and both BSR and NRAS will provide this evidence to NICE and NHSE to inform their decision making as we move forward in our discussion on this important topic.’ NRAS have recently revised their position statement on biosimilars which can be found here.